Stocks Health care SNOA
NASDAQ · Health careSonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc. brought in $21.9M of revenue over the twelve months to June 30, 2026, up 47.0% from a year earlier. It posted a net loss of $2.3M. In fiscal 2026 capital spending exceeded operating cash flow by $4.1M. At June 30, 2026 it held $5.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Sonoma Pharmaceuticals, Inc.
- Net worth
- Sonoma Pharmaceuticals, Inc. has a market value (market cap) of $5.9M at the latest share price, and shareholders' equity of $6.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $19.5M (+36.7% year on year), with a net loss of $3.2M. Over the 12 months to June 30, 2026: revenue $21.9M, net loss $2.3M.
- Cash flow
- In fiscal 2026 operations used $3.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sonoma Pharmaceuticals, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
What Sonoma Pharmaceuticals, Inc. does
Sonoma Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker SNOA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $19.5M | -$3.2M | -$1.89 | -$4.1M |
| 2025 | $14.3M | -$3.5M | -$2.79 | -$168K |
| 2024 | $12.7M | -$4.8M | -$10.63 | -$2.4M |
| 2023 | $13.3M | -$5.2M | -$30.49 | -$6.4M |
| 2022 | $12.6M | -$5.1M | -$38.51 | -$4.4M |
| 2021 | $18.6M | -$4M | -$39.51 | -$3.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SNOA ranks in Health care
Latest SEC filings
What Sonoma Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Form 8-A12B/A filing 8-A12B/A
- October 6, 2026Material agreement8-KSonoma Pharmaceuticals adopted a new Section 382 rights agreement to protect its net operating loss tax assets.
- September 17, 2026
- August 19, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 60% to $6.4M versus the same quarter last year; diluted EPS -$0.09 versus -$0.76.
- July 28, 2026Proxy statement DEF 14A
- July 23, 2026Additional proxy material DEFA14A
- July 9, 2026
- June 24, 2026Additional proxy material DEFA14A
- June 18, 2026Other event 8-K
Insider trades
What the people running Sonoma Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about SNOA
What does Sonoma Pharmaceuticals, Inc. do?
Sonoma Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as SNOA. Its shares trade on NASDAQ under the ticker SNOA.
What is Sonoma Pharmaceuticals, Inc.'s net worth?
Sonoma Pharmaceuticals, Inc. has a market value (market cap) of $5.9M at the latest share price, and shareholders' equity of $6.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sonoma Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $2.3M on revenue of $21.9M.
How much revenue does Sonoma Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Sonoma Pharmaceuticals, Inc. reported revenue of $21.9M. That is 47.0% more than a year earlier.
When did Sonoma Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form 8-A12B/A filing from October 6, 2026.
When is Sonoma Pharmaceuticals, Inc.'s next earnings report?
Sonoma Pharmaceuticals, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare SNOA with
Follow SNOA
Get an email when Sonoma Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sonoma Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.